|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Bellicum Pharmaceuticals, Inc (BLCM) |
|
|
$0.07 0.00 (0.00%) as of 4:30 Mon 3/4
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
6,100,000 |
Market
Cap: |
455.98(K) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.0745 - $0.56 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. Co. is developing chimeric antigen receptors (CAR)-T cell therapies, which are an approach in which a patient's or donor's T cells are genetically modified to carry CARs. By incorporating its switch technologies, Co. is developing product candidates in various areas of cellular immunotherapy including BPX-601, which is designed to treat solid tumors expressing prostate stem cell antigen; and BPX-603, which is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Spencer David M. |
Chief Scientific Officer |
|
2016-09-22 |
4 |
AS |
$19.68 |
$196,832 |
D/D |
(10,000) |
162,282 |
|
- |
|
Spencer David M. |
Chief Scientific Officer |
|
2016-09-21 |
4 |
AS |
$20.04 |
$6,012 |
D/D |
(300) |
172,282 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2016-09-21 |
4 |
AS |
$20.04 |
$2,004 |
D/D |
(100) |
344 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2016-09-21 |
4 |
OE |
$7.47 |
$747 |
D/D |
100 |
444 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-09-21 |
4 |
AS |
$20.04 |
$2,004 |
I/I |
(100) |
366,940 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-09-21 |
4 |
AS |
$20.04 |
$2,004 |
D/D |
(100) |
95,464 |
|
- |
|
Spencer David M. |
Chief Scientific Officer |
|
2016-09-20 |
4 |
AS |
$20.00 |
$2,000 |
D/D |
(100) |
172,582 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-09-20 |
4 |
AS |
$20.00 |
$2,000 |
I/I |
(100) |
367,040 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-09-20 |
4 |
AS |
$20.00 |
$6,000 |
D/D |
(300) |
95,564 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2016-09-20 |
4 |
AS |
$20.00 |
$4,000 |
D/D |
(200) |
344 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2016-09-20 |
4 |
OE |
$7.47 |
$1,494 |
D/D |
200 |
544 |
|
- |
|
Spencer David M. |
Chief Scientific Officer |
|
2016-09-19 |
4 |
AS |
$20.02 |
$14,013 |
D/D |
(700) |
172,682 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-09-19 |
4 |
AS |
$20.01 |
$24,129 |
I/I |
(1,206) |
367,140 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-09-19 |
4 |
AS |
$20.02 |
$28,024 |
D/D |
(1,400) |
95,864 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2016-09-19 |
4 |
AS |
$20.01 |
$26,018 |
D/D |
(1,300) |
344 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2016-09-19 |
4 |
OE |
$7.47 |
$9,711 |
D/D |
1,300 |
1,644 |
|
- |
|
Spencer David M. |
Chief Scientific Officer |
|
2016-09-16 |
4 |
AS |
$20.01 |
$34,015 |
D/D |
(1,700) |
173,382 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-09-16 |
4 |
AS |
$20.00 |
$12,720 |
I/I |
(636) |
368,346 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-09-16 |
4 |
AS |
$20.00 |
$18,840 |
D/D |
(942) |
97,264 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2016-09-16 |
4 |
AS |
$20.00 |
$14,000 |
D/D |
(700) |
344 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2016-09-16 |
4 |
OE |
$7.47 |
$5,229 |
D/D |
700 |
1,044 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-08-15 |
4 |
AS |
$19.27 |
$598,931 |
I/I |
(31,000) |
368,982 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-08-15 |
4 |
AS |
$19.27 |
$695,012 |
D/D |
(36,000) |
98,206 |
|
- |
|
Spencer David M. |
Chief Scientific Officer |
|
2016-08-15 |
4 |
AS |
$20.00 |
$20,000 |
D/D |
(1,000) |
175,082 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2016-08-15 |
4 |
AS |
$20.00 |
$20,000 |
D/D |
(1,000) |
344 |
|
- |
|
179 Records found
|
|
Page 5 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|